Cargando…

Relationship between raltegravir trough plasma concentration and virologic response and the impact of therapeutic drug monitoring during pregnancy

BACKGROUND: Limited data is available on raltegravir (RAL) pharmacokinetics during pregnancy and the value of therapeutic drug monitoring (TDM) in pregnancy is unknown. This study aims to describe RAL trough plasma concentrations (C(trough)) during pregnancy and review the impact of RAL TDM on outco...

Descripción completa

Detalles Bibliográficos
Autores principales:	Carvalho, Sabrina, Sheehan, Nancy L., Valois, Silvie, Kakkar, Fatima, Boucher, Marc, Ferreira, Ema, Boucoiran, Isabelle
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2022
Materias:	Original Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9925909/ https://www.ncbi.nlm.nih.gov/pubmed/36529684 http://dx.doi.org/10.1177/09564624221144489

Ejemplares similares

115. Results of a Targeted Neonatal Screening Program for Congenital Cytomegalovirus Infection in Montreal, Quebec
por: Renaud, Christian, et al.
Publicado: (2018)

A case series of third-trimester raltegravir initiation: Impact on maternal HIV-1 viral load and obstetrical outcomes
por: Boucoiran, I, et al.
Publicado: (2015)

No association between early antiretroviral therapy during pregnancy and plasma levels of angiogenic factors: a cohort study
por: Djeha, Ameyo, et al.
Publicado: (2019)

Impact of maternal HIV-1 viremia on lymphocyte subsets among HIV-exposed uninfected infants: protective mechanism or immunodeficiency
por: Kakkar, Fatima, et al.
Publicado: (2014)

Clinical and genetic determinants of nevirapine plasma trough concentration
por: Giacomelli, Andrea, et al.
Publicado: (2018)

Clinical, immunological, and virological outcomes in HIV patients on raltegravir-based salvage therapy
por: Deshwal, Rajesh, et al.
Publicado: (2019)

High-Trough Plasma Concentration of Afatinib Is Associated with Dose Reduction
por: Takahashi, Takayuki, et al.
Publicado: (2021)

886. Pregnancy Outcomes Following Raltegravir Exposure
por: Shamsuddin, Hala, et al.
Publicado: (2019)

Risk factors for pre-term birth in a Canadian cohort of HIV-positive women: role of ritonavir boosting?
por: Kakkar, Fatima, et al.
Publicado: (2015)

2487. Low Rate of Virologic Failure in Antiretroviral Experienced Patients Prescribed Once Daily Raltegravir
por: Hsu, Ricky, et al.
Publicado: (2019)

462. Differences in the Humoral Response to SARS-CoV-2 Infection in Children vs. Adult
por: Mentor, Girlande, et al.
Publicado: (2021)

Raltegravir Cerebrospinal Fluid Concentrations in HIV-1 Infection
por: Yilmaz, Aylin, et al.
Publicado: (2009)

Clinical, virological and immunological responses in Danish HIV patients receiving raltegravir as part of a salvage regimen
por: Engsig, Frederik N, et al.
Publicado: (2010)

Effectiveness and Risk Factors for Virological Outcome of Raltegravir-Based Therapy for Treatment-Experienced HIV-Infected Patients
por: Mata-Marín, José Antonio, et al.
Publicado: (2017)

HIV-1 resistance patterns to integrase inhibitors in Chilean patients with virological failure on raltegravir-containing regimens
por: Ferrer, Pablo, et al.
Publicado: (2020)

Virologic failure after 48 weeks of raltegravir-based regimen in low HIV-1 incidence setting
por: Chehadeh, Wassim, et al.
Publicado: (2020)

Virologic Outcomes Among ART-Naïve Individuals Initiating Dolutegravir, Elvitegravir, Raltegravir or Darunavir: An Observational Study
por: Mills, Anthony M., et al.
Publicado: (2019)

Raltegravir monohydrate
por: Yamuna, Thammarse S., et al.
Publicado: (2013)

Plasma Peak and Trough Gentamicin Concentrations in Hospitalized Horses Receiving Intravenously Administered Gentamicin
por: Bauquier, J.R., et al.
Publicado: (2015)

Plasma Trough Concentrations of Antihypertensive Drugs for the Assessment of Treatment Adherence: A Meta-Analysis
por: Groenland, Eline H., et al.
Publicado: (2020)

Interactive Effects of Glucocorticoids and Cytochrome P450 Polymorphisms on the Plasma Trough Concentrations of Voriconazole
por: Jia, Su-jie, et al.
Publicado: (2021)

The effect of inflammation on voriconazole trough concentrations in children
por: ter Avest, Mendy, et al.
Publicado: (2016)

HIV resistance to raltegravir
por: Clavel, François
Publicado: (2009)

Brief Report: Switch to Ritonavir-Boosted Atazanavir Plus Raltegravir in Virologically Suppressed Patients With HIV-1 Infection: A Randomized Pilot Study
por: van Lunzen, Jan, et al.
Publicado: (2016)

Association of Voriconazole Trough Plasma Concentration with Efficacy and Incidence of Hepatotoxicity in Iranian Patients with Hematological Malignancies
por: Taghvaye-masoumi, Hamidreza, et al.
Publicado: (2021)

Raltegravir plus abacavir/lamivudine in virologically suppressed HIV-1-infected patients: 48-week results of the KIRAL study
por: Troya, Jesús, et al.
Publicado: (2018)

Elevated Vancomycin Trough Concentration: Increased Efficacy and/or Toxicity?
por: Elyasi, Sepideh, et al.
Publicado: (2014)

High levels of polymorphisms related to raltegravir resistance among raltegravir-naïve individuals in Brazil
por: Pena, N Mantovani, et al.
Publicado: (2010)

Loading regimen required to rapidly achieve therapeutic trough plasma concentration of teicoplanin and evaluation of clinical features
por: Seki, Masafumi, et al.
Publicado: (2012)

Drug-drug interactions with raltegravir
por: Burger, David M
Publicado: (2009)

Raltegravir in treatment naïve patients
por: Cossarini, F, et al.
Publicado: (2009)

Raltegravir use in special populations
por: Johnson, Margaret
Publicado: (2009)

Adverse events of raltegravir and dolutegravir
por: Elzi, Luigia, et al.
Publicado: (2017)

Evaluation of Neural Tube Defects (NTDs) After Exposure to Raltegravir During Pregnancy
por: Shamsuddin, Hala, et al.
Publicado: (2019)

Health outcomes and the transition experience of HIV-infected adolescents after transfer to adult care in Québec, Canada
por: Kakkar, Fatima, et al.
Publicado: (2016)

Trough Concentrations of Vancomycin in Patients Undergoing Extracorporeal Membrane Oxygenation
por: Park, So Jin, et al.
Publicado: (2015)

An Ensemble Model for Prediction of Vancomycin Trough Concentrations in Pediatric Patients
por: Huang, Xiaohui, et al.
Publicado: (2021)

Raltegravir 1200 mg once daily as maintenance therapy in virologically suppressed HIV-1 infected adults: QDISS open-label trial
por: Hall, Nolwenn, et al.
Publicado: (2022)

Correlation Between Trough Plasma Dabigatran Concentrations and Estimates of Glomerular Filtration Rate Based on Creatinine and Cystatin C
por: Chin, Paul K. L., et al.
Publicado: (2014)

Relation between Plasma Trough Concentration of Pazopanib and Progression-Free Survival in Metastatic Soft Tissue Sarcoma Patients
por: Minot-This, Marie-Sophie, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_rc2fgdsiqi2ipo0sad3ddk86hs